These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 7022510)
1. Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man. Karim SM; Adaikan PG; Lau LC; Tai MY Prostaglandins Med; 1981 May; 6(5):521-7. PubMed ID: 7022510 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet aggregation with intravenous and oral administration of a carboprostacyclin analogue, 15-cyclopentyl-omega-pentanor-5(E)-carbacyclin (ONO 41483) in man. Adaikan PG; Lau LC; Tai MY; Karim SM Prostaglandins Leukot Med; 1983 Jan; 10(1):53-64. PubMed ID: 6338531 [TBL] [Abstract][Full Text] [Related]
3. Platelet and other effects of carboprostacyclin--a stable prostacyclin analogue. Adaikan PG; Karim SM; Lau LC Prostaglandins Med; 1980 Oct; 5(4):307-20. PubMed ID: 7003626 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates. Adaikan PG; Kottegoda SR; Lau LC; Tai MY; Karim SM Prostaglandins Leukot Med; 1982 Sep; 9(3):307-20. PubMed ID: 6752959 [TBL] [Abstract][Full Text] [Related]
5. Effects of intravenous infusion of prostacyclin (PGI2) in man. O'Grady J; Warrington S; Moti MJ; Bunting S; Flower R; Fowle AS; Higgs EA; Moncada S Prostaglandins; 1980 Feb; 19(2):319-32. PubMed ID: 6992228 [TBL] [Abstract][Full Text] [Related]
6. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Whittle BJ; Moncada S; Whiting F; Vane JR Prostaglandins; 1980 Apr; 19(4):605-27. PubMed ID: 6992234 [TBL] [Abstract][Full Text] [Related]
7. The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey. Allan G; Follenfant MJ; Lidbury P; Oliver PL; Whittle BJ Br J Pharmacol; 1985 Jun; 85(2):547-55. PubMed ID: 3896365 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet aggregation and antagonism of vasopressin-induced ECG changes in primates by a carboprostacyclin analogue, ZK 36374. Adaikan PG; Karim SM; Lau LC; Tai MY; Kottegoda SR Thromb Res; 1984 Feb; 33(3):333-40. PubMed ID: 6200948 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2). Orchard MA; Ritter JM; Shepherd GL; Lewis PJ Br J Clin Pharmacol; 1983 May; 15(5):509-11. PubMed ID: 6344895 [TBL] [Abstract][Full Text] [Related]
10. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man. Hassan S; Pickles H; Fish A; Burke C; Warrington S; O'Grady J Br J Clin Pharmacol; 1982 Sep; 14(3):369-77. PubMed ID: 6127095 [TBL] [Abstract][Full Text] [Related]
11. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man. O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004 [TBL] [Abstract][Full Text] [Related]
12. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers. Reele SB; Miller OV; Spillers C; Gorman RR Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420 [TBL] [Abstract][Full Text] [Related]
13. Effect of Iloprost (ZK 36 374), a novel prostacyclin analogue, on ADP-induced platelet aggregation. Wadenvik H; Kutti J Acta Haematol; 1985; 73(4):224-7. PubMed ID: 2414956 [TBL] [Abstract][Full Text] [Related]
15. Anti-platelet action of intravenous infusion of prostacyclin in man. Gryglewski RJ; Szczeklik A; Nizankowski R Thromb Res; 1978 Aug; 13(2):153-63. PubMed ID: 358486 [No Abstract] [Full Text] [Related]
16. Inhibition of platelet aggregation by a new agent, 5-(Z,E)-13,14-didehydro-20-methyl-carbo PGI2 (FCE 22509). Bergamaschi M; Pierucci L; Ferti C; Corsi G; Branzoli U; Mandelli V Prostaglandins Leukot Med; 1984 Oct; 16(1):19-27. PubMed ID: 6393142 [TBL] [Abstract][Full Text] [Related]
17. Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole. Pickles H; Fish A; Hassan S; Burke C; Warrington S; O'Grady J Clin Pharmacol Ther; 1983 Feb; 33(2):178-82. PubMed ID: 6337004 [TBL] [Abstract][Full Text] [Related]
18. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin. Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the vasodepressor action of ZK 36 374, a stable prostacyclin derivative, PGI2 and PGE1 with their effect on platelet aggregation and bleeding time in rats. Casals-Stenzel J; Buse M; Losert W Prostaglandins Leukot Med; 1983 Feb; 10(2):197-212. PubMed ID: 6189133 [TBL] [Abstract][Full Text] [Related]
20. Effects of prostacyclin on platelet aggregation as studied with "filter-loop" technique in the flowing blood of the dog. Imai S; Matsubara I Artery; 1980; 8(1):63-72. PubMed ID: 7000043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]